All In Biotech

Investigational drug · Phase 2

EXG110

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Fabry Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "EXG110"

First trial start

2025

Mar 1, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "EXG110", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Fabry Disease

Approved drugs for the same conditions: Fabry disease · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "EXG110" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Fabry Disease

  • VenglustatGZ402671Phase 35 trials

    Sanofi · Fabry Disease, Gaucher's Disease Type III, Gaucher Disease Type 1

  • LucerastatPhase 32 trials

    Idorsia Pharmaceuticals Ltd. · Fabry Disease

  • 4D-310Phase 22 trials

    4D Molecular Therapeutics · Fabry Disease

  • AMT-191Phase 21 trial

    UniQure Biopharma B.V. · Fabry Disease

  • ST-920Phase 21 trial

    Sangamo Therapeutics · Fabry Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.